Simulations Plus (NASDAQ:SLP) Updates FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.07-$1.20 for the period, compared to the consensus EPS estimate of $1.01. The company issued revenue guidance of $90-$93 million, compared to the consensus revenue estimate of $90.71 million.

Simulations Plus Stock Performance

SLP stock traded up $1.29 on Tuesday, reaching $30.39. The company had a trading volume of 471,065 shares, compared to its average volume of 274,444. The company’s fifty day moving average is $29.78 and its 200 day moving average is $34.16. The company has a market cap of $610.38 million, a P/E ratio of 62.02 and a beta of 0.80. Simulations Plus has a 1 year low of $27.07 and a 1 year high of $51.22.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. During the same quarter in the previous year, the company posted $0.18 EPS. The firm’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, sell-side analysts predict that Simulations Plus will post 1.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SLP has been the topic of several research reports. BTIG Research cut their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, Stephens initiated coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Simulations Plus currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Insiders Place Their Bets

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares of the company’s stock, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 19.40% of the stock is owned by insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.